DK1330468T3 - Svovlanaloger af 21 hydroxy-6,19-oxido-progesteron (21OH 6OP) til behandling af overskud af glucocorticoider - Google Patents

Svovlanaloger af 21 hydroxy-6,19-oxido-progesteron (21OH 6OP) til behandling af overskud af glucocorticoider

Info

Publication number
DK1330468T3
DK1330468T3 DK01969729T DK01969729T DK1330468T3 DK 1330468 T3 DK1330468 T3 DK 1330468T3 DK 01969729 T DK01969729 T DK 01969729T DK 01969729 T DK01969729 T DK 01969729T DK 1330468 T3 DK1330468 T3 DK 1330468T3
Authority
DK
Denmark
Prior art keywords
hydroxy
treatment
oxido
progesterone
sulfur analogs
Prior art date
Application number
DK01969729T
Other languages
English (en)
Inventor
Gerardo Burton
Carlos P Lantos
Adriana Silvia Veleiro
Original Assignee
Serono Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Lab filed Critical Serono Lab
Application granted granted Critical
Publication of DK1330468T3 publication Critical patent/DK1330468T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0073—Sulfur-containing hetero ring
    • C07J71/0078—Sulfur-containing hetero ring containing only sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK01969729T 2000-09-18 2001-09-17 Svovlanaloger af 21 hydroxy-6,19-oxido-progesteron (21OH 6OP) til behandling af overskud af glucocorticoider DK1330468T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00119495 2000-09-18
PCT/EP2001/010750 WO2002022647A1 (en) 2000-09-18 2001-09-17 Sulphur analogues of 21-hydroxy-6,19-oxidoprogesterone (21oh-6op) for treating excess of glucocorticoids

Publications (1)

Publication Number Publication Date
DK1330468T3 true DK1330468T3 (da) 2007-11-05

Family

ID=8169775

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01969729T DK1330468T3 (da) 2000-09-18 2001-09-17 Svovlanaloger af 21 hydroxy-6,19-oxido-progesteron (21OH 6OP) til behandling af overskud af glucocorticoider

Country Status (14)

Country Link
US (2) US7053228B2 (da)
EP (1) EP1330468B1 (da)
JP (1) JP2004509132A (da)
AT (1) ATE368683T1 (da)
AU (1) AU8988901A (da)
CA (1) CA2419887C (da)
CY (1) CY1107756T1 (da)
DE (1) DE60129725T2 (da)
DK (1) DK1330468T3 (da)
ES (1) ES2288987T3 (da)
IL (2) IL154775A0 (da)
PT (1) PT1330468E (da)
SI (1) SI1330468T1 (da)
WO (1) WO2002022647A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1330468T3 (da) * 2000-09-18 2007-11-05 Serono Lab Svovlanaloger af 21 hydroxy-6,19-oxido-progesteron (21OH 6OP) til behandling af overskud af glucocorticoider
US7071328B2 (en) * 2000-09-18 2006-07-04 Applied Research System Ars Holding N.V. Method for the preparation of 21-hydroxy-6,19-oxidoprogesterone (21 oh-6op)
CN102190607A (zh) * 2010-03-15 2011-09-21 北京化工大学 一种农药除草剂中间体乙磺酰基乙腈的绿色合成方法
EP2413115A1 (en) * 2010-07-30 2012-02-01 Technische Universiteit Eindhoven Generating a control signal based on acoustic data

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4910191A (en) * 1988-06-28 1990-03-20 Merrell Dow Pharmaceuticals Inc. 19-substituted progesterone derivatives useful as 19-hydroxylase inhibitors
CZ307995A3 (en) * 1993-05-24 1996-10-16 Immunex Corp Ligands for flt3 receptors
PT903148E (pt) 1997-09-21 2002-02-28 Schering Corp Terapia de combinacao para a erradicacao de rna de hcv detectavel em doentes tendo infeccao cronica pelo virus da hepatite c
EP0903146A1 (en) * 1997-09-23 1999-03-24 Applied Research Systems ARS Holdings N.V. 21-Hydroy-6,19-oxidoprogesterone (210h-60p) as antiglucocorticoid
CN1173703C (zh) * 1999-04-23 2004-11-03 里奥药物制品有限公司 药物组合物
DK1330468T3 (da) 2000-09-18 2007-11-05 Serono Lab Svovlanaloger af 21 hydroxy-6,19-oxido-progesteron (21OH 6OP) til behandling af overskud af glucocorticoider
US7071328B2 (en) 2000-09-18 2006-07-04 Applied Research System Ars Holding N.V. Method for the preparation of 21-hydroxy-6,19-oxidoprogesterone (21 oh-6op)

Also Published As

Publication number Publication date
WO2002022647A1 (en) 2002-03-21
IL154775A0 (en) 2003-10-31
CA2419887C (en) 2009-11-10
US20040029846A1 (en) 2004-02-12
DE60129725T2 (de) 2007-12-06
CY1107756T1 (el) 2013-09-04
PT1330468E (pt) 2007-09-13
EP1330468A1 (en) 2003-07-30
US7479486B2 (en) 2009-01-20
CA2419887A1 (en) 2002-03-21
ES2288987T3 (es) 2008-02-01
EP1330468B1 (en) 2007-08-01
US7053228B2 (en) 2006-05-30
IL154775A (en) 2010-12-30
ATE368683T1 (de) 2007-08-15
AU8988901A (en) 2002-03-26
US20050222104A1 (en) 2005-10-06
JP2004509132A (ja) 2004-03-25
DE60129725D1 (de) 2007-09-13
SI1330468T1 (sl) 2007-10-31

Similar Documents

Publication Publication Date Title
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
DK1309593T3 (da) Substituerede pyrazoler
ATE247464T1 (de) Neue fettanaloge zur behandlung der fettleibigkeit
DE69914726D1 (de) Zusammensetzung zur regulierung des hauterscheinungsbildes
EA200900663A1 (ru) Лечение синдрома "сухого глаза"
DE50115490D1 (de) Kosmetische zusammensetzung zur behandlung von alternder und/oder gestresster haut
DK1309592T3 (da) Substituerede pyrazoler
DK1411932T3 (da) Kombinationsterapi med substituerede oxazolidinoner
ATE303156T1 (de) Verwendung von gnrh-analogue zur behandlung der harninkontinenz
MY135841A (en) Novel benzodioxoles
BRPI0006634B8 (pt) composição tópica compreendendo extrato de matricária no tratamento e prevenção de distúrbios inflamatórios
MY147643A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
DK1237549T3 (da) Lipoxin A4 og dets analoger til behandling af törre öjne
CY1110644T1 (el) 5,6,7-τριυδροξυεπτανοϊκο οξυ και τα αναλογα για την θεραπεια οφθαλμικων ασθενειων που σχετιζονται με υπερεκφυτικες και αγγειογενεις αντιδρασεις
NO984950D0 (no) Forbindelser med veksthormonfrigj°rende egenskaper
ATE422892T1 (de) Verwendung von hyaluronsäure zur herstellung von zusammensetzungen zur behandlung rekurrenten aphthen in der mundhöhle
CY1107756T1 (el) Αναλογα θειου της 21-υδροξυ-6, 19-οξειδοπρογεστερονης (21oh-6οp) για τη θεραπεια πλεονασματος γλυκοκορτικοειδων
EE05124B1 (et) Toimeainena dotsetakseeli v?i selle hdraati sisaldava kompositsiooni kasutamine
SE0004101D0 (sv) New use
DE602006012115D1 (de) Behandlung von amyotrophischer lateralsklerose mit pyrimethamin und analoga
ATE409491T1 (de) Orhthalmologische zusammenstellungen zur behandlung von ocularer hypertension
MXPA03010737A (es) Aril-8-azabiciclo(3.2.1) octanos para tratamiento de depresion.
ATE347536T1 (de) Chlorsilanblends zur behandlung von quarzfuellstoffen
EA200700979A1 (ru) Пероральные твердые лекарственные формы, содержащие низкую дозу эстрадиола
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen